Biotest
Yves Ohandja (PhD) has extensive work experience in quality assurance and regulatory affairs within the pharmaceutical and medical device industry. Yves was employed by Biotest AG from 2017, where they held the positions of Senior Manager GxP Compliance and later Head Of Quality Assurance Operations - Development Projects. Prior to that, they worked at Immucor, Inc. from 2013 as the Manager Quality and Regulatory Affairs Europe.
Yves Ohandja (PhD) earned a Doctor of Philosophy (PhD) degree in Biochemistry and Molecular Biology from Zhejiang University in Hangzhou, China, where they studied from 2007 to 2011.
This person is not in any teams
This person is not in any offices
Biotest
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.